Mechanism of action: Trihexyphenidyl balliculeVisual mnemonic: Trihexyphenidyl mascot “Triangle-hexagon Art thing” “mad as a hatter” → BBB-crossing antimuscarinic
What it isCentral antimuscarinic; drug-induced parkinsonism, dystonia and tremor.
Why this oneEffective for dystonia, including the primary dystonias, where few oral agents work.
What limits itAnticholinergic burden and cognitive impairment, so it is poor in the elderly. It does not help tardive dyskinesia and can worsen it.
Molecular structure: Trihexyphenidyl
Trihexyphenidyl prescription history
Animated chart of estimated U.S. prescriptions per year, Parkinson medicines (1948–2026). Trihexyphenidyl enters in 1949 (estimated).
FDA-approved for
Parkinson disease / drug-induced EPS (1949)
Off-label
primary dystonia
Principal riskAnticholinergic burden and cognitive impairment
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.